Scarica l'app Stockscreener
3.24
3.86%
-0.13
Pre-mercato:
3.25
0.010
+0.31%
Precedente Chiudi:
$3.37
Aprire:
$3.37
Volume 24 ore:
316.99K
Relative Volume:
0.95
Capitalizzazione di mercato:
$273.66M
Reddito:
$351.37M
Utile/perdita netta:
$-135.96M
Rapporto P/E:
-1.9756
EPS:
-1.64
Flusso di cassa netto:
$-85.40M
1 W Prestazione:
+2.86%
1M Prestazione:
+1.57%
6M Prestazione:
-9.24%
1 anno Prestazione:
-9.24%
Intervallo 1D:
$3.24
$3.39
Intervallo di 1 settimana:
$3.16
$3.485
Portata 52W:
$2.75
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
857-204-8109
Indirizzo
225 FRANKLIN STREET, BOSTON
Confronta AVIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.24 | 273.66M | 351.37M | -135.96M | -85.40M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9% - MarketBeat
Franklin Berger Increases Stake in Atea Pharmaceuticals Inc (AVI - GuruFocus.com
Barclays PLC Buys 75,624 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Barclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals Targets $3B HCV Market with Phase 3 Trial Launch, Backed by $454M Cash - StockTitan
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals CEO to Present Business Update at J.P. Morgan Healthcare Conference - StockTitan
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Decreased by Geode Capital Management LLC - Defense World
Barclays PLC Increases Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat
State Street Corp Purchases 11,566 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
US Penny Stocks To Watch In December 2024 - Simply Wall St
Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions - StockTitan
Atea Pharmaceuticals engages Evercore to explore partnerships - MSN
Analyzing Atea Pharmaceuticals (NASDAQ:AVIR) & Alnylam Pharmaceuticals (NASDAQ:ALNY) - Defense World
Atea Pharmaceuticals, Inc. Engages Evercore to Identify Potential Opportunities to Enhance Shareholder Value, Including the Exploration of Strategic Partnerships Related to Its Phase 3-Ready Program for the Treatment of Hepatitis C Virus - Marketscreener.com
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewswire
Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program - StockTitan
Charles Schwab Investment Management Inc. Acquires 50,794 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock By Investing.com - Investing.com Nigeria
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock - Investing.com
Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals stock hits 52-week low at $2.88 By Investing.com - Investing.com Australia
Atea Pharmaceuticals stock hits 52-week low at $2.88 - Investing.com
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Yahoo Finance
Atea Aims For Underserved HCV Niche With Combo Regimen - News & Insights
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Yahoo Finance
Atea reports high efficacy in Phase 2 HCV treatment study - Investing.com
Atea Pharmaceuticals Announces Positive Results from Phase - GlobeNewswire
Atea's HCV Drug Achieves 98% Cure Rate in Phase 2 Trial, Shows Breakthrough Promise - StockTitan
Atea plans Phase 3 study for hepatitis C drug after mid-stage results - Yahoo Finance
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Atea Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | AVIR Stock News - StockTitan
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - MSN
Island Pharmaceuticals Advances Dengue Clinical Trial - MSN
Atomo Diagnostics Plans Share Issuance to Boost Capital - MSN
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
Appian Cl A Sees RS Rating Improve To 72 - MSN
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):